Latest news with #WAKIX
Yahoo
10-07-2025
- Business
- Yahoo
H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 30, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $70.00. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The company reported strong fiscal Q1 2025 results, with net revenue for WAKIX (pitolisant) in narcolepsy reaching $184.7 million for the quarter, reflecting a 20% year-over-year growth. It projects 2025 net revenue to be in the range of $820 to $860 million. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also experienced a 19% year-over-year increase in net income, building on four consecutive years of profitability. It increased its cash and investments to more than $600 million on the balance sheet. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
26-06-2025
- Business
- Yahoo
Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on June 6 and set a price target of $49.00. The analyst based the rating on the company's promising developments and data, citing the preclinical data for BP1.15205. Presented at the SLEEP 2025 conference, the data highlights significant clinical activity in an orexin/ataxin-3 mouse model, with no noted safety concerns and a wide therapeutic index. This is a positive factor for the drug's efficacy, as it points towards the potential for nearly complete wakefulness at low doses. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The analyst further supported the optimistic rating for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) with comparative data from other compounds, such as ORX750 and TAK-861, which demonstrated promising results with considerable wakefulness and a reduction in cataplexy episodes. All these factors contribute to a bullish outlook for the company's pipeline for addressing unmet needs in sleep disorders. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on June 6 and set a price target of $49.00. The analyst based the rating on the company's promising developments and data, citing the preclinical data for BP1.15205. Presented at the SLEEP 2025 conference, the data highlights significant clinical activity in an orexin/ataxin-3 mouse model, with no noted safety concerns and a wide therapeutic index. This is a positive factor for the drug's efficacy, as it points towards the potential for nearly complete wakefulness at low doses. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The analyst further supported the optimistic rating for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) with comparative data from other compounds, such as ORX750 and TAK-861, which demonstrated promising results with considerable wakefulness and a reduction in cataplexy episodes. All these factors contribute to a bullish outlook for the company's pipeline for addressing unmet needs in sleep disorders. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
09-06-2025
- Business
- Yahoo
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory
We came across a bullish thesis on Harmony Biosciences Holdings, Inc. (HRMY) on Capital Curiosity's Substack by Taylor Nichols. In this article, we will summarize the bulls' thesis on HRMY. Harmony Biosciences Holdings, Inc. (HRMY)'s share was trading at $35.03 as of 5th June. HRMY's trailing and forward P/E were 13.37 and 9.45 respectively according to Yahoo Finance. Copyright: zneb076 / 123RF Stock Photo Harmony Biosciences stands out as an overlooked gem in the small-cap biotech space, combining strong financials with pipeline potential in a niche therapeutic area. With a $2 billion market cap and a focus on rare neurological diseases, Harmony's flagship drug WAKIX for narcolepsy has underpinned impressive fundamentals—35% revenue CAGR since 2020, 25% net margins, and consistent free cash flow conversion above 30%. Despite these metrics, the stock trades at just 13x earnings and an EV/EBITDA of 7.9x, reflecting investor scepticism largely tied to single-product dependency and unresolved legal risks from 2023 fraud allegations. Still, Harmony boasts over $480 million in cash, negligible debt, and a stable share count, which enhances confidence in long-term shareholder returns. While WAKIX remains the core revenue driver, the company is aggressively diversifying through M&A, including the Zynerba and Epygenix acquisitions, bringing promising assets like ZYN002 for Fragile X Syndrome into the pipeline. Phase 3 data expected in Q3 2025 could catalyze upside, alongside the development of Pitolisant HD and other preclinical candidates. A DCF valuation incorporating conservative assumptions yields share prices between $38 and $62, implying a substantial upside from current levels. Analyst sentiment is bullish, with eight of nine recent ratings being buys and a $51 average price target. Although risks like competition from Jazz Pharmaceuticals, FDA hurdles, and prolonged legal overhang remain, Harmony's profitability, cash strength, and strategic execution offer investors a compelling asymmetrical opportunity. For those seeking exposure to a profitable, underappreciated rare disease player with both pipeline and financial momentum, Harmony merits close attention. Previously, we covered a on Harmony Biosciences by Long-Access-2143 in April 2025, which aligns with Taylor Nichols' analysis. The stock has seen an appreciation of approximately 13% since then. Both highlight WAKIX's strength and undervaluation, while Long-Access-2143 stresses the mispricing post short-seller attack and details a WAKIX-driven DCF, Nichols places more emphasis on pipeline expansion and cash strength. Together, they reinforce Harmony's appeal as a profitable, underappreciated biotech. Harmony Biosciences Holdings, Inc. (HRMY) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 27 hedge fund portfolios held HRMY at the end of the first quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of HRMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
Harmony Biosciences settles generic drug litigation, strengthens patent
Harmony Biosciences (HRMY) announced a settlement agreement with Lupin Limited, resolving patent infringement litigation related to Lupin's Abbreviated New Drug Application for a generic version of WAKIX. Under the agreement, Lupin will receive a license to launch its generic product no earlier than January 2030 (or July 2030 with pediatric exclusivity), or earlier under certain circumstances. Harmony asserted multiple patents covering WAKIX, its FDA-approved treatment for excessive daytime sleepiness or cataplexy in adults and pediatric patients with narcolepsy. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on HRMY: Disclaimer & DisclosureReport an Issue Harmony Biosciences Settles Patent Dispute with Lupin Harmony Biosciences assumed with an Outperform at Oppenheimer Harmony Biosciences Holds 2025 Annual Stockholders Meeting Harmony Biosciences price target raised to $48 from $44 at Mizuho Harmony Biosciences Holdings: Strong Market Position and Growth Potential Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
